Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to Pegvisomant | Zendy

Ariel L. Barkan | Zendy; Pia Burman | Zendy; David R. Clemmons | Zendy; William Drake | Zendy; Robert F. Gagel | Zendy; Philip E. Harris | Zendy; Peter Trainer | Zendy; Aart Jan van der Lely | Zendy; Mary Lee Vance | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to Pegvisomant

Author(s) -

Ariel L. Barkan,

Pia Burman,

David R. Clemmons,

William Drake,

Robert F. Gagel,

Philip E. Harris,

Peter Trainer,

Aart Jan van der Lely,

Mary Lee Vance

Publication year - 2005

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2005-0331

Subject(s) - pegvisomant , acromegaly , medicine , octreotide , endocrinology , glycemic , diabetes mellitus , glucose homeostasis , somatostatin , population , liter , glucose clamp technique , insulin resistance , pancreatic hormone , hormone , growth hormone , environmental health

In clinical practice, patients with acromegaly may be switched from therapy with long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on glucose homeostasis and safety has not been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research